ArticleBiosafety and health2025
Development of an in-house dual RT-qPCR assay for detecting SFTSV and Hantaan virus simultaneously.
Article in Biosafety and health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Establishment and application of a rapid and visual detection method forBiosafety and health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Given the overlapping endemic regions and clinical similarities between severe fever with thrombocytopenia syndrome (SFTS) and hemorrhagic fever with renal syndrome (HFRS), we developed a dual real-time fluorescence-based reverse transcription quantitative polymerase chain reaction (RT-qPCR) method. Recombinant plasmids and synthetic ribonucleic acid (RNA) were constructed to evaluate the specificity, sensitivity and reproducibility of the assay. Additionally, we assessed the specificity of the assay using samples from three distinct groups: individuals with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (n = 10), influenza A-positive individuals (n = 10), and healthy controls. Receiver operating characteristic (ROC) curves were used to assess diagnostic accuracy, while the Kappa coefficient and linear regression analysis were employed to evaluate clinical applicability. Our method exhibited specificity for both SFTSV and Hantaan virus detection, with detection limits of 333 and 1,022 copies/mL using plasmids, and 1,247 and 898 copies/mL using synthetic RNA, respectively. We evaluated 100 clinical samples from each of SFTS and HFRS. The Kappa coefficients for both diseases were 0.96. The areas under the ROC curves were 0.991 (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.